Abstract
1H-NMR metabolomics data is increasingly used to track various aspects of health and disease. With the availability of larger data resources and continuously improving learning algorithms Nightingale Health has recently updated the quantification and calibration strategy of their platform to further align their reported analytes with clinical standards. Such updates, however, might influence backward replicability and could hamper comparison of repeated measures in longitudinal studies. Based on data of the BBMRI.nl consortium (>25.000 samples across 28 studies), we compared Nightingale data, as originally released in 2014 and 2016, with a re-quantified version of this data released in 2020, of which both versions were based on the same original NMR spectra. Apart from 2 discontinued, and 23 newly defined analytes, we overall observe a high concordance between quantification versions, with 73 out of 222 (33%) showing a mean correlation > 0.9 across the 28 Dutch cohorts. Nevertheless, five metabolites consistently showed relatively low correlations (R<0.7) between platform versions, namely acetoacetate (acace), LDL particle size (ldl_d), saturated fatty acids percentage (sfa_fa), S-HDL-C (s_hdl_c) and sphingomyelins (sm). Previously trained multi-analyte scores, such as our previously published health predictors MetaboAge or MetaboHealth, might be particularly sensitive to platform changes. Whereas the MetaboHealth score replicated well between platform versions, the MetaboAge score indeed had to be retrained due to discontinued metabolites. Notably, both scores projected on the 2020 re-quantified data did recapitulate the original mortality associations observed in the previous version of the data. Concluding, we urge caution when utilizing data from different quantification versions to avoid mixing analytes capturing different underlying aspects of the NMR spectra, having different units, or simply being discontinued.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was performed within the framework of the BBMRI Metabolomics Consortium funded by BBMRI.NL (a research infrastructure financed by the Dutch government, NWO 184.021.007 and 184.033.111), by X-omics (NWO 184.034.019), VOILA (ZonMW 457001001) and Medical Delta (scientific program METABODELTA: Metabolomics for clinical advances in the Medical Delta). EvdA is funded by a personal grant of the Dutch Research Council (NWO; VENI: 09150161810095). A full list of acknowledgements for all the contributing studies can be found in the Supplementary Materials (Acknowledgements).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Alpha Omega Cohort The protocol of the Alpha Omega Trial, from which the Alpha Omega Cohort emerged, was approved by the Medical Ethics Review Committee of Haga Hospital ″Leyenburg″, The Hague (METC Zuidwest Holland; L01.049) and by local ethics committees of all participating hospitals. In accordance with the Declaration of Helsinki, the Alpha Omega Cohort obtained informed consent from all participants prior to their entering the study. Amsterdam Dementia Cohort The Amsterdam Dementia Cohort study protocol was approved by the Medical Ethics Committee of VU University Medical Centre (2016.061). In accordance with the Declaration of Helsinki, the Amsterdam Dementia Cohort obtained informed consent from all participants prior to their entering the study. BIOMARCS The BIOMarker study to identify the Acute risk of a Coronary Syndrome (BIOMArCS) study protocol was approved by the Medical Ethics Committee of the Erasmus MC (MEC–2007–185). In accordance with the Declaration of Helsinki, the BIOMarker study to identify the Acute risk of a Coronary Syndrome (BIOMArCS) obtained informed consent from all participants prior to their entering the study. LUMINA The study protocols making up the Leiden University MIgraine Neuro–Analysis (LUMINA) cohort were approved by the Medisch Ethische Toetsingcommissie (METC) of the Leiden University Medical Center (LUMC) (registration numbers P07.079 and P12.113). In accordance with the Declaration of Helsinki, the LUMINA CSF, MRS, and CHARM subcohorts obtained informed consent from all participants prior to their entering the study. CHECK Cohort Heup en Cohort Knie study protocol was approved by Medical ethics committees of all participating centres. In accordance with the Declaration of Helsinki, the Cohort Heup en Cohort Knie obtained informed consent from all participants prior to their entering the study. CODAM The Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study protocol was approved by the Medical Ethics Review Committee of the AzM/UM (MEC 99–112 /MEC05–170). In accordance with the Declaration of Helsinki, the CODAM study btained informed consent from all participants prior to their entering the study The Maastricht Study (TMS) The Maastricht Study protocol was approved by the Medical Ethics Review Committee AzM/UM (NL31329.068.10) and the Minister of Health, Welfare and Sports of the Netherlands (Permit 131088–105234–PG). In accordance with the Declaration of Helsinki, the Maastricht Study obtained informed consent from all participants prior to their entering the study. The Hoorn Diabetes Care System cohort study (DCS) The Hoorn Diabetes Care System Cohort study protocol was approved by the ethical committee VU Vrije Universiteit Medical Center (2007/57). In accordance with the Declaration of Helsinki, the The Hoorn Diabetes Care System Cohort obtained informed consent from all participants prior to their entering the study. Erasmus Rucphen Family (ERF) study The Erasmus Rucphen Family study protocol was approved by the Medical Ethics Committee of the Erasmus MC Rotterdam, the Netherlands (MEC 213.575/2002/114). In accordance with the Declaration of Helsinki, the Erasmus Rucphen Family study obtained informed consent from all participants prior to their entering the study. Rotterdam Study The Rotterdam Study protocol was approved by the Medical Ethics Committee of the Erasmus MC Rotterdam, the Nethrlands. (MEC 02.1015) and by the Dutch Ministry of Health, Welfare, and Sport (Population Screening Act WBO, license number 1071272–159521–PG). In accordance with the Declaration of Helsinki, the Rotterdam Study obtained written informed consent from all participants prior to their entering the study. FUNCTGENOMICS The 500 Functional Genomics study protocol was approved by Commissie Mensgebonden Onderzoek Regio Arnhem–Nijmegen (42561.091.12). In accordance with the Declaration of Helsinki, the 500 Functional Genomics study obtained informed consent from all participants prior to their entering the study. GARP The Genetics, ARthrosis and Progression study protocol was approved by the Medical Ethic Committee of the LUMC (P 76/98). In accordance with the Declaration of Helsinki, the Genetics, ARthrosis and Progression obtained informed consent from all participants prior to their entering the study. HELIUS The HEalthy LIfe in an Uran Society (HELIUS) study protocol was approved by the Medical Ethics Board of the Amsterdam University Medical Centers, location AMC (METC 10/100#10.17.1729). In accordance with the Declaration of Helsinki, the HEalthy LIfe in an Uran Society study obtained informed consent from all participants prior to their entering the study. LIFELINES–DEEP The LifeLines DEEP study was approved by the ethics committee of the University Medical Center Groningen, document number METC UMCG LLDEEP: M12.113965. All participants signed an informed consent form before study enrollment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Leiden Longevity Study (LLS) The Leiden Longevity Study protocol was approved by the Medical Ethical Committee of the Leiden University Medical Center before the start of the study (P01.113). In accordance with the Declaration of Helsinki, the Leiden Longevity Study obtained informed consent from all participants prior to their entering the study. NESDA The Netherlands Study of Depression and Anxiety (NESDA) was approved by the Medical Ethical Committee of the VUmc (reference number 2003/183). In accordance with the Declaration of Helsinki, the Netherlands Study of Depression and Anxiety obtained informed consent from all participants prior to their entering the study. PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) The Prospective study of Pravastatin in the Elderly at Risk protocol was approved by institutional ethics review boards of centres of Cork University (Ireland), Glasgow University (Scotland) and Leiden University Medical Center (the Netherlands). In accordance with the Declaration of Helsinki, the The Prospective study of Pravastatin in the Elderly at Risk obtained informed consent from all participants prior to their entering the study. The LUMC arthroplasty studies RAAK Research Artrotisch Articulair Kraakbeen study protocol was approved by Medical Ethics Committee of the LUMC (P08.239 and P19.013). In accordance with the Declaration of Helsinki, the Research Artrotisch Articulair Kraakbeen obtained informed consent from all participants prior to their entering the study. TACTICS The 'Kwaliteit van leven en morbiditeit 10 jaar na totale heup of knie vervanging' study protocol was approved by Medical Ethics Committee of the LUMC (P00.179 and P11.050). In accordance with the Declaration of Helsinki, the Kwaliteit van leven en morbiditeit 10 jaar na totale heup of knie vervanging obtained informed consent from all participants prior to their entering the study. TOMAAT The 'Transfusie op maat studie – optimale bloedmanagement bij electieve orthopedische ingrepen' study protocol was approved by Medical Ethics Committee of the LUMC (P03.044). In accordance with the Declaration of Helsinki, the Transfusie op maat studie – optimale bloedmanagement bij electieve orthopedische ingrepen obtained informed consent from all participants prior to their entering the study. STEMI_GIPS–III The Glycometabolic Intervention as Adjunct to Primary Percutaneous Coronary Intervention in ST– Segment Elevation Myocardial Infarction (GIPS) III study is a double–blind placebo–controlled randomized clinical trial and was designed to determine whether metformin preserves left ventricular function after ST–segment elevation myocardial infaction (STEMI) in patients without diabetes. The study protocol was in accordance with the Declaration of Helsinki and was approved by the institutional review board (METC 2010.077, Groningen, the Netherlands) and national regulatory authorities. This trial was registered at clinicaltrials.gov (NCT01217307). UCORBIO Utrecht Coronary Biobank Study (UCORBIO) study protocol was approved by the Medical Ethics Committee of the UMC Utrecht (reference number 11–183). In accordance with the Declaration of Helsinki, the Utrecht Coronary Biobank Study (UCORBIO) obtained informed consent from all participants prior to their entering the study. VUNTR The Netherlands twin Register study protocol was approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Centre, Amsterdam, an Institutional Review Board certified by the U.S. Office of Human Research Protections (IRB number IRB00002991 under Federal–wide Assurance– FWA00017598. In accordance with the Declaration of Helsinki, the Netherlands Twin Register obtained informed consent from all participants prior to their entering the study. HOF The HOF study ″Prenatal nutrition and adult disease, an analysis of sib–pairs discordant for exposure to the Dutch famine of 1944–1945″ was approved by the Institutional Review Board of Columbia University, New York (IRB–AAAB4053) and by the Medical Ethics Committee of Leiden University Medical Center (P02.082). Written informed consent was obtained from all study participants. STABILITEIT The Amsterdam Dementia Cohort study protocol, from which the STABILITEIT cohort emerged, was approved by the Medical Ethics Committee of VU University Medical Centre (2016.061). In accordance with the Declaration of Helsinki, the Amsterdam Dementia Cohort obtained informed consent from all participants prior to their entering the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to BBMRI-nl.
